BGB-11417-101: Latest Trial now open at LINEAR Research Institute!

BGB-11417-101: Latest Trial now open at LINEAR Research Institute!

BGB-11417-101:
Latest Trial now open at LINEAR Research Institute!

In humans, the BCL2 gene helps regulate cell death or life. A specific protein called Bcl-2 is pro-survival, helping to keep cells alive. Some cancer cells express to much BCL-2 protein, which reduces the cells death response. Over-expression of the protein is a common finding in leukaemias and lymphomas

This phase 1 study offers patients with mature B-Cell malignancies a tablet of BGB-11417 which is a Bcl-2 inhibitor. This drug is a 2nd generation Bcl-2 inhibitor, other Bcl-2 inhibitor currently used in lymphomas and leukaemias have shown very promising results.

For more information about this trial, visit our website: www.bloodcancerwa.org/trials

#cancer #bloodcancer #bloodcancerresearchwa #clinicaltrials #perth #westernaustralia #savinglives

Share this post